文献速递心脏核医学肿瘤 PET/CT

FDG PET/CT上包括心外病变部位在内的半定量代谢值可预测心脏结节病患者的治疗过程

Semi-quantitative metabolic values on FDG PET/CT including extracardiac sites of disease as a predictor of treatment course in patients with cardiac sarcoidosis.
PubMed 文献 · EJNMMI Res · 2017-08-18

该回顾性研究纳入16例疑似心脏结节病且心脏炎症FDG PET/CT显示心肌异常活动、随后接受皮质类固醇治疗的患者,比较所有可视器官系统的高代谢病灶半定量值与6个月时每日皮质类固醇剂量的关系。结果显示,所有可视器官系统(包括心脏)的最大SUV在皮质类固醇剂量≤10 mg组为8.8 ± 3.1,>10 mg组为12.5 ± 3.3(P = 0.04);而代谢体积和TLG在两组间无显著统计学差异。结论认为,胸部及上腹部所有受累器官系统的最大SUV(而非仅心脏的最大SUV)可能预测活动性心脏结节病患者6个月时类固醇治疗的治疗过程。

要点

  • 16例患者中81.3%(13/16)存在心外受累。
  • 所有可视器官系统最大SUV:皮质类固醇剂量≤10 mg组8.8 ± 3.1 vs >10 mg组12.5 ± 3.3(P = 0.04)。
  • 代谢体积和TLG在所有器官系统或心脏单独均无显著统计学差异。

核心结论

  • 胸部及上腹部所有受累器官系统的最大SUV(而非仅心脏的最大SUV)可能预测活动性心脏结节病患者6个月时类固醇治疗的治疗过程。

研究设计与样本

  • 回顾性研究纳入16例连续患者,均为疑似心脏结节病、心脏炎症FDG PET/CT显示心肌异常活动且涵盖整个胸部/上腹部、随后接受皮质类固醇治疗以诊断活动性心脏结节病。

主要发现

  • 16例患者中81.3%(13/16)显示心外受累。
  • 最大SUV病灶位于心脏者11例(68.7%),位于肝脏者1例(6.3%),位于淋巴结者4例(25%)。
  • 所有可视器官系统(包括心脏)的最大SUV在皮质类固醇剂量≤10 mg组为8.8 ± 3.1,在>10 mg组为12.5 ± 3.3(P = 0.04)。
  • 所有可视器官系统或心脏单独的代谢体积和TLG在两组间无显著统计学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac sarcoidosis is associated with major adverse cardiac events including cardiac arrest, for which anti-inflammatory treatment is indicated. Oral corticosteroid is the mainstay among treatment options; however, adverse effects are a major concern with long-term use. It would be beneficial for providers to predict treatment response and prognosis for proper management strategy of sarcoidosis, though it remains challenging. Fluorine (F)-18 fluorodeoxyglucose (FDG)-positron emission tomography(PET)/computed tomography(CT) has an advantage over anatomical imaging in providing semi-quantitative functional parameters such as standard uptake value (SUV), metabolic volume, and total lesion glycolysis (TLG), which are well-established biomarkers in oncology. However, the relationship between these parameters and treatment response has not been fully investigated in cardiac sarcoidosis. Also, the prognostic value of extracardiac active inflammation noted on FDG-PET/CT in the setting of cardiac sarcoidosis is unclear. The aim of this retrospective study was to investigate the prognostic value of semi-quantitative values of both cardiac and extracardiac disease sites derived from FDG-PET/CT in predicting treatment course in cardiac sarcoidosis. METHODS: Sixteen consecutive patients with suspected cardiac sarcoidosis, who demonstrated abnormal myocardial activity on cardiac-inflammation FDG-PET/CT encompassing the entire chest/upper abdomen and subsequently underwent corticosteroid therapy for diagnosis of active cardiac sarcoidosis, were included. Semi-quantitative values of hypermetabolic lesions were derived from all visualized organ system and were compared to daily corticosteroid dose at 6 months. RESULTS: Of the 16 patients, 81.3% (13/16) of the patients showed extracardiac involvement. The lesion with the greatest SUV was identified in the heart in 11 patients (68.7%), in the liver in 1 patient (6.3%), and in lymph nodes in 4 patients (25%). The maximum SUV across all visualized organ systems including the heart were 8.8 ± 3.1 for the patients with corticosteroid dose ≤ 10 mg and 12.5 ± 3.3 for those with > 10 mg (P = 0.04). Metabolic volume and TLG across all visualized organ systems or any values in the heart alone showed no significant statistical difference between the two groups. CONCLUSIONS: Maximum SUV across all involved organ-systems of the chest and upper abdomen, not that of the heart alone, could be a predictor of treatment course of steroid therapy at 6 months in patients with active cardiac sarcoidosis.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ishiyama M, Soine LA, Vesselle HJ, et al. Semi-quantitative metabolic values on FDG PET/CT including extracardiac sites of disease as a predictor of treatment course in patients with cardiac sarcoidosis. EJNMMI Res. 2017. PMID: 28822108. doi:10.1186/s13550-017-0315-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。